Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 399

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 399
---
 Rewell platform independent of a growing number of specialists that would increase linearly with the number of users, and thus increase costs. To achieve this, we are exploring various machine learning models and LLMs for automatic customer segmentation, generation of recommendations, and habit planning, which can be curated by the nutrigenetic specialists. We are developing AI Agents using LLM technology to assist users within the platform, and designing solutions that leverage the entire set of user information (genetic, microbiome, habit questionnaires) to enhance the sense of personalization. These initiatives reflect our dedication to delivering superior and actionable health analytics, fostering a deeper engagement with our users, and maintaining our commitment to innovation in the field of genomic health. Heritas Reproductive Genetics: Carrier Screening This product would implement carrier genetic testing to complement and strengthen our portfolio in the field of reproductive genetics. Carrier testing is an important genetic test when planning a family because it helps to determine the risk of having a child with a genetic disease. It determines if a user and their partner or donor are carriers of single -generecessive conditions. In addition, if a user and their partner, or donor, both carry the same mutation, the probability of having a sick child is 25%. Through this project, we would be able to combine all reproductive genetic tests in an all -in -onegenetic test solution, which includes carrier screening to prenatal testing, aimed at couples planning a family. Reproductive Genetics: PGT-A This initiative would implement preimplantation genetic testing to complement and further strengthen the portfolio of solutions of our reproductive genomics portfolio. PGT -Ais a genetic test performed on embryos to identify numerical chromosomal abnormalities (aneuploidy), which are detected prior to embryo transfer to enable informed decisions and increase pregnancy success. This project is currently establishing the technical conditions to deploy pilot testing in patients in Argentina. Oncology: Solid Tumor CGP (Comprehensive Genomic Profile) Through our exclusive Commercialization Agreement with CIBIC, who works on a shared project with F. Hoffmann -LaRoche AG (“Roche”), we are advancing a project to integrate a genomic profiling panel into routine diagnostics for solid tumors in Argentina. This project leverages Roche’s proprietary technology and the proven capabilities of the FoundationOne® CDx panel to provide comprehensive genomic insights from tissue samples. In Argentina, CIBIC will be responsible for providing the commercial channels and may provide supplies for processing samples in certain cases, while we will manage the technology implementation and